JP2002528412A5 - - Google Patents

Download PDF

Info

Publication number
JP2002528412A5
JP2002528412A5 JP2000578001A JP2000578001A JP2002528412A5 JP 2002528412 A5 JP2002528412 A5 JP 2002528412A5 JP 2000578001 A JP2000578001 A JP 2000578001A JP 2000578001 A JP2000578001 A JP 2000578001A JP 2002528412 A5 JP2002528412 A5 JP 2002528412A5
Authority
JP
Japan
Prior art keywords
drug
endoplasmic reticulum
agent
protein
misassembled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000578001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002528412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/025221 external-priority patent/WO2000024391A2/en
Publication of JP2002528412A publication Critical patent/JP2002528412A/ja
Publication of JP2002528412A5 publication Critical patent/JP2002528412A5/ja
Pending legal-status Critical Current

Links

JP2000578001A 1998-10-27 1999-10-27 分泌通路を通る不適当に折り畳まれたタンパク質のコンダクタンス Pending JP2002528412A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10580698P 1998-10-27 1998-10-27
US60/105,806 1998-10-27
PCT/US1999/025221 WO2000024391A2 (en) 1998-10-27 1999-10-27 Conductance of improperly folded proteins through the secretory pathway

Publications (2)

Publication Number Publication Date
JP2002528412A JP2002528412A (ja) 2002-09-03
JP2002528412A5 true JP2002528412A5 (cg-RX-API-DMAC7.html) 2006-12-28

Family

ID=22307893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000578001A Pending JP2002528412A (ja) 1998-10-27 1999-10-27 分泌通路を通る不適当に折り畳まれたタンパク質のコンダクタンス

Country Status (6)

Country Link
US (1) US6344475B1 (cg-RX-API-DMAC7.html)
EP (1) EP1126832A2 (cg-RX-API-DMAC7.html)
JP (1) JP2002528412A (cg-RX-API-DMAC7.html)
AU (1) AU775575B2 (cg-RX-API-DMAC7.html)
CA (1) CA2348529A1 (cg-RX-API-DMAC7.html)
WO (1) WO2000024391A2 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236300A1 (en) * 1999-10-27 2003-12-25 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20040266883A1 (en) * 1999-10-27 2004-12-30 Yale University Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US20020132770A1 (en) * 1999-10-27 2002-09-19 Caplan Michael T. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
US6867459B2 (en) * 2001-07-05 2005-03-15 Isonics Corporation Isotopically pure silicon-on-insulator wafers and method of making same
US7119400B2 (en) * 2001-07-05 2006-10-10 Isonics Corporation Isotopically pure silicon-on-insulator wafers and method of making same
US20040171226A1 (en) * 2001-07-05 2004-09-02 Burden Stephen J. Isotopically pure silicon-on-insulator wafers and method of making same
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
FR2876584B1 (fr) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
US8859020B2 (en) 2005-05-30 2014-10-14 Benny Antony Treatment of alzheimer's with a curcuminoid mixture and essential oil of turmeric having 45% Ar-turmerone
US10286027B2 (en) 2005-05-30 2019-05-14 Arjuna Natural Extracts, Ltd. Sustained release formulations of curcuminoids and method of preparation thereof
US7883728B2 (en) 2005-05-30 2011-02-08 Arjuna Natural Extracts, Ltd. Composition to enhance the bioavailability of curcumin
US10543277B2 (en) 2005-05-30 2020-01-28 Arjuna Natural Private Limited Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof
US12053438B2 (en) 2005-05-30 2024-08-06 Arjuna Natural Private Limited Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof
US9492402B2 (en) 2005-05-30 2016-11-15 Benny Antony Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof
DK1890546T3 (en) 2005-05-30 2019-03-11 Benny Antony Process for improving the bioavailability of curcumin
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
EP2190850A4 (en) * 2007-07-03 2011-03-09 Univ British Columbia DELTAF508 CFTR DELTAF508 DELTAFLECTIVE TRANSPORTATION MOLECULES
GB0809360D0 (en) * 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
RU2637101C2 (ru) * 2016-01-11 2017-11-29 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии" (ФГБНУ ФИЦВиМ) Устройство для определения аспирированной дозы аэрозолей
CN116240239B (zh) * 2023-04-18 2024-12-27 华东师范大学 程序可控的蛋白质快速分泌释放系统及其构建方法和应用
CN116476541B (zh) * 2023-05-16 2025-12-02 征图新视(江苏)科技股份有限公司 一种针对光学膜卷材的高速打标系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8704089D0 (en) 1987-02-21 1987-03-25 Fisons Plc Method of treatment
US5674898A (en) * 1990-03-05 1997-10-07 Genzyme Corporation Methods and therapeutic compositions for treating cystic fibrosis
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
WO1993013768A1 (en) 1992-01-06 1993-07-22 Ariad Pharmaceuticals, Inc. Therapeutic uses of thiol-oxidizing agents and sulfhydryl-alkylating agents
US5384128A (en) 1993-03-02 1995-01-24 University Of Alabama Research Foundation Method of and compounds for treatment for cystic fibrosis
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5691306A (en) 1993-08-26 1997-11-25 National Research Council Of Canada Methods of detection and treatment of protein trafficking disorders and increasing secretory protein production
DE69535673D1 (de) * 1994-08-30 2008-02-07 Univ Dundee Mittel zur induktion von apoptosis und zur therapieanwendung
WO1996036334A1 (en) * 1995-05-19 1996-11-21 University Of East Anglia Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6015828A (en) 1996-05-31 2000-01-18 Cuppoletti; John Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases
US5985824A (en) 1997-02-27 1999-11-16 Genzyme Corporation Methods and compositions for treating cystic fibrosis

Similar Documents

Publication Publication Date Title
Yagiela et al. Comparison of myotoxic effects of lidocaine with epinephrine in rats and humans
Mackenzie et al. Current strategies for retarding progression of renal disease
Lau et al. Inhibition of caspase-mediated apoptosis by peroxynitrite in traumatic brain injury
Malmqvist et al. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide
EE200100505A (et) Modifitseeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis, hüdrofiilnekontrollitud vabanemisega preparaat, selle valmistamismeetod ja kasutamine ning ravimvorm
IE61182B1 (en) Pharmaceutical compositions containing ibuprofen in combination with a piperidinoalkanol antihistamine
Morisco et al. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double-blind controlled study
Policicchio et al. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine
Rengo et al. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension
Goa et al. Lisinopril: A review of its pharmacology and use in the management of the complications of diabetes mellitus
Brogden et al. Moexipril: a review of its use in the management of essential hypertension
McKeage et al. Manidipine: a review of its use in the management of hypertension
Cogolludo et al. New insights in the pharmacological therapy of arterial hypertension
Ninci et al. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study
AU2003287488B2 (en) Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally
Messerli Moxonidine: a new and versatile antihypertensive
Noa et al. A comparative study of policosanol vs lovastatin on intimal thickening in rabbit cuffed carotid artery
Manolis et al. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo
Malhotra et al. Barnidipine
MXPA02009819A (es) El uso de un bloqueante de los canales de calcio para tratamiento de trastornos renales.
JPH10510528A (ja) 骨関節炎を治療するためのジクロフェナック及びトリベノサイドの併用
JP2002503687A5 (cg-RX-API-DMAC7.html)
Anderson et al. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients
Fenton et al. Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension
Lee et al. Systemic absorption of insulin from a Gelfoam® ocular device